Literature DB >> 17673495

New paradigms for treatment development.

Ellen L Stover1, Linda Brady, Stephen R Marder.   

Abstract

Wayne Fenton believed that government-particularly National Institute of Mental Health (NIMH)-could play a critical role in addressing important public health problems where the current system of treatment development was inadequate. Earlier experiences in HIV/AIDS convinced him and others that the NIMH can effectively facilitate the rapid development of new research in critical areas. This report will demonstrate how the work of Fenton and others brought together representatives from industry, government, and academia to address issues that included new preclinical approaches to drug development and defining new therapeutic targets in schizophrenia. An initiative to facilitate the development of new pharmacological agents to address the cognitive impairments in schizophrenia-titled Measurement and Treatment Research to Improve Cognition in Schizophreniaor MATRICS-is used as an example of a new paradigm for treatment development.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17673495      PMCID: PMC2632353          DOI: 10.1093/schbul/sbm085

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  23 in total

Review 1.  Interventions to Prevent HIV Risk Behaviors. NIH Consensus Development Conference. February 11-13, 1997.

Authors: 
Journal:  AIDS       Date:  2000-09       Impact factor: 4.177

2.  Medicine. What are the right targets for psychopharmacology?

Authors:  Steven E Hyman; Wayne S Fenton
Journal:  Science       Date:  2003-01-17       Impact factor: 47.728

3.  Reliability and validity of the positive and negative syndrome scale for schizophrenics.

Authors:  S R Kay; L A Opler; J P Lindenmayer
Journal:  Psychiatry Res       Date:  1988-01       Impact factor: 3.222

4.  One hundred years of schizophrenia: a meta-analysis of the outcome literature.

Authors:  J D Hegarty; R J Baldessarini; M Tohen; C Waternaux; G Oepen
Journal:  Am J Psychiatry       Date:  1994-10       Impact factor: 18.112

5.  Translation of appropriateness criteria into practice guidelines: application of decision table techniques to the RAND criteria for coronary artery bypass graft.

Authors:  R N Shiffman; L L Leape; R A Greenes
Journal:  Proc Annu Symp Comput Appl Med Care       Date:  1993

6.  The Brief Psychiatric Rating Scale for Children.

Authors:  J E Overall; B Pfefferbaum
Journal:  Psychopharmacol Bull       Date:  1982-04

Review 7.  Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Authors:  Michael F Green; Keith H Nuechterlein; James M Gold; Deanna M Barch; Jonathan Cohen; Susan Essock; Wayne S Fenton; Fred Frese; Terry E Goldberg; Robert K Heaton; Richard S E Keefe; Robert S Kern; Helena Kraemer; Ellen Stover; Daniel R Weinberger; Steven Zalcman; Stephen R Marder
Journal:  Biol Psychiatry       Date:  2004-09-01       Impact factor: 13.382

Review 8.  Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.

Authors:  Philip D Harvey; Michael F Green; Richard S E Keefe; Dawn I Velligan
Journal:  J Clin Psychiatry       Date:  2004-03       Impact factor: 4.384

9.  The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy.

Authors:  P F Liddle
Journal:  Br J Psychiatry       Date:  1987-08       Impact factor: 9.319

Review 10.  What are the functional consequences of neurocognitive deficits in schizophrenia?

Authors:  M F Green
Journal:  Am J Psychiatry       Date:  1996-03       Impact factor: 18.112

View more
  7 in total

1.  Identifying unmet therapeutic domains in schizophrenia patients: the early contributions of Wayne Fenton from Chestnut Lodge.

Authors:  Thomas H McGlashan; William T Carpenter
Journal:  Schizophr Bull       Date:  2007-07-18       Impact factor: 9.306

Review 2.  NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders.

Authors:  Linda S Brady; Lois Winsky; Wayne Goodman; Mary Ellen Oliveri; Ellen Stover
Journal:  Neuropsychopharmacology       Date:  2008-09-17       Impact factor: 7.853

3.  Cognitive deficits in schizophrenia: short-term and long-term.

Authors:  John M Kane; Todd Lencz
Journal:  World Psychiatry       Date:  2008-02       Impact factor: 49.548

4.  The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?

Authors:  Robert W Buchanan; Richard S E Keefe; Daniel Umbricht; Michael F Green; Thomas Laughren; Stephen R Marder
Journal:  Schizophr Bull       Date:  2010-04-21       Impact factor: 9.306

Review 5.  The evolution of drug development in schizophrenia: past issues and future opportunities.

Authors:  William T Carpenter; James I Koenig
Journal:  Neuropsychopharmacology       Date:  2007-11-28       Impact factor: 7.853

6.  Single transcranial direct current stimulation in schizophrenia: Randomized, cross-over study of neurocognition, social cognition, ERPs, and side effects.

Authors:  Yuri Rassovsky; Walter Dunn; Jonathan K Wynn; Allan D Wu; Marco Iacoboni; Gerhard Hellemann; Michael F Green
Journal:  PLoS One       Date:  2018-05-07       Impact factor: 3.240

7.  Adjuvant therapy with minocycline for schizophrenia (The MINOS Trial): study protocol for a double-blind randomized placebo-controlled trial.

Authors:  Abebaw Fekadu; Miraf Mesfin; Girmay Medhin; Atalay Alem; Solomon Teferra; Tsehaysina Gebre-Eyesus; Teshale Seboxa; Abraham Assefa; Jemal Hussein; Martha T Lemma; Christina Borba; David C Henderson; Charlotte Hanlon; Teshome Shibre
Journal:  Trials       Date:  2013-11-27       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.